Myriad Genetics, Inc.
MYGN
Market Cap$2.23B
Close$
$-2.59
110.2% downside
Current Fair Value
110.2% downsideOvervalued by 110.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.23 Billion |
|---|---|
| Enterprise Value | $2.16 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-2.76 |
| Beta | 1.5 |
| Outstanding Shares | 90,507,981 |
| Avg 30 Day Volume | 937,313 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -9.49 |
|---|---|
| PEG | 18.1 |
| Price to Sales | 3.16 |
| Price to Book Ratio | 3.16 |
| Enterprise Value to Revenue | 2.79 |
| Enterprise Value to EBIT | -17.97 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
ESG Score
No data
About Myriad Genetics, Inc.
2,600 employees
CEO: R. Bryan Riggsbee Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accura...